Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock; No Amount Given

Protalix BioTherapeutics, Inc. PLX announced today that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for the offering and each of Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotment, if any.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!